Peripheral blood stem cell mobilization with granulocyte colony-stimulating factor and a harvesting procedure in pediatric donors.

abstract：:We describe the rare occurrence of a granulomatous pneumonitis seen in a patient following allogeneic bone marrow transplantation. Interestingly sarcoidosis was diagnosed in the marrow donor less than a year after donating his bone marrow. ...

journal_title：Bone marrow transplantation

authors： Sundar KM,Carveth HJ,Gosselin MV,Beatty PG,Colby TV,Hoidal JR

更新日期：2001-09-01 00:00:00

abstract：:To evaluate the efficacy and toxicity of two different etoposide (VP-16) dosages (30 or 45 mg/kg) in combination with busulfan/cyclophosphamide as conditioning therapy followed by stem cell transplantation in acute myeloid leukemia (AML), 90 patients with AML received either 30 mg/kg (n = 60) or 45 mg/kg (n = 30) etop...

journal_title：Bone marrow transplantation

authors： Kröger N,Zabelina T,Sonnenberg S,Krüger W,Renges H,Stute N,Finkenstein F,Mayer U,Holstein K,Fiedler W,Colberg H,Sonnen R,Kuse R,Braumann D,Metzner B,del Valle F,Erttmann R,Kabisch H,Zander AR

更新日期：2000-10-01 00:00:00

abstract：:Multiple clinical studies have been undertaken to evaluate the role of ABMT in relapse, in second and subsequent remission (CR greater than or equal to 2), and in first remission (CR1). The value of these high dose cytoreductive programs with ABMT is not yet known. No randomized studies have been done yet indicating t...

journal_title：Bone marrow transplantation

authors： Dicke KA,Spinolo JA

更新日期：1989-01-01 00:00:00

abstract：:beta-Thalassemia major and sickle cell disease (SCD) are among the most common hereditary disorders worldwide. The supportive treatment of beta-thalassemia major requires chronic, life-long RBC transfusions, which cause progressive iron overload and the potential for impaired endocrine, cardiac and hepatic function. T...

journal_title：Bone marrow transplantation

authors： Bhatia M,Walters MC

更新日期：2008-01-01 00:00:00

abstract：:Whereas patients with multiple myeloma continue to relapse after autologous transplantation and are unlikely to be cured, the probability of progression is less after allogeneic transplantation and a proportion of patients may be cured. This is attributable to an immunologically mediated graft-versus-myeloma (GVM) eff...

journal_title：Bone marrow transplantation

authors： Mehta J,Singhal S

更新日期：1998-11-01 00:00:00

abstract：:In the 1980s it became clear that low numbers of primitive hematopoietic cells were present in the peripheral bloodstream. Early clinical trials by investigators in the USA, Australia, and Germany demonstrated that these cells could be collected and reinfused to support high-dose chemotherapy procedures in patients ot...

journal_title：Bone marrow transplantation

authors： Shea TC

更新日期：1999-05-01 00:00:00

abstract：:The underlying plasma cell clones in multiple myeloma (MM) and Ig light-chain amyloidosis (AL) appear to be different not only in terms of 'tumor burden' but also in terms of their underlying biology. High-dose chemotherapy with auto-SCT is one method of reducing the clone size and thereby improving OS. Post-auto-SCT ...

journal_title：Bone marrow transplantation

authors： Dispenzieri A,Seenithamby K,Lacy MQ,Kumar SK,Buadi FK,Hayman SR,Dingli D,Litzow MR,Gastineau DA,Inwards DJ,Micallef IN,Ansell SM,Johnston PB,Porrata LF,Patnaik MM,Hogan WJ,Gertz MA

更新日期：2013-10-01 00:00:00

abstract：:Human fetal livers from 6 to 13 weeks postconception were analysed before and after cryopreservation. The percentages of cell subsets, detected by MoAbs, did not change significantly after cryopreservation. Compared with BM, fetal liver contained significantly smaller subsets of cells identified by MoAbs, with two exc...

journal_title：Bone marrow transplantation

authors： Ek S,Ringdén O,Markling L,Dahlberg N,Pschera H,Seiger A,Sundström E,Westgren M

更新日期：1993-05-01 00:00:00

abstract：:Current graft-versus-host disease (GVHD) prophylaxis is not uniformly successful. Since the development of GVHD has a profound impact on transplant success, treatment is required. The mainstay of therapy has been glucocorticoids (steroids), along with anti-thymocyte globulin, cyclosporine, monoclonal antibodies, and a...

journal_title：Bone marrow transplantation

authors： Deeg HJ,Henslee-Downey PJ

更新日期：1990-07-01 00:00:00

abstract：:We report the cases of two severe aplastic anemia (SAA) patients who were successfully treated with syngeneic peripheral blood stem cell transplantation (PBSCT) using immunosuppression without high-dose chemotherapy or irradiation for conditioning. A 21-year-old woman with SAA of 6 years duration had been transfused h...

journal_title：Bone marrow transplantation

authors： Hwang WL,Yang Y,Chen GR,Tsai CS,Jour JH

更新日期：2000-02-01 00:00:00

abstract：:Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder which results from absence or malfunction of the respiratory burst oxidase normally expressed in neutrophils and other phagocytic leukocytes. Two-thirds of the patients are males hemizygous for mutations in the X-linked gene coding for gp91-pho...

journal_title：Bone marrow transplantation

authors： Grez M,Becker S,Saulnier S,Knöss H,Ott MG,Maurer A,Dinauer MC,Hoelzer D,Seger R,Hossle JP

更新日期：2000-05-01 00:00:00

abstract：:A 55-year-old man with acute myeloid leukemia in second relapse presented 4 months after haploidentical CD34+-selected hematopoietic stem cell transplantation (HSCT) with symmetric, progressive neurological deficits of the lower extremities. Although there was no molecular evidence for drug resistance in the cerebral-...

journal_title：Bone marrow transplantation

authors： Zeiser R,Grüllich C,Bertz H,Pantazis G,Hufert FT,Bley TA,Finke J

更新日期：2004-01-01 00:00:00

abstract：:Autologous stem cell transplantation (PBSCT) is standard for young patients in MM and its TRM has decreased after the 2000s. Bortezomib and immunomodulatory agents (IMiDs) in MM have improved the outcome. However, they seem to boost pro-inflammatory stage increasing the incidence of engraftment syndrome (ES). Favorabl...

journal_title：Bone marrow transplantation

authors： Gutiérrez-García G,Rovira M,Magnano L,Rosiñol L,Bataller A,Suárez-Lledó M,Cibeira MT,de Larrea CF,Garrote M,Jorge S,Moreno A,Rodríguez-Lobato LG,Carreras E,Díaz-Ricart M,Palomo M,Martínez C,Urbano-Ispizua A,Bladé J,Fe

更新日期：2018-12-01 00:00:00

abstract：:Sequential administration of high-dose chemotherapy courses possibly allows extensive in vivo purging before circulating progenitor collection for autograft. To evaluate whether progenitor cell mobilization was negatively affected by repeated high-dose chemotherapy courses, we studied 23 lymphoma patients undergoing t...

journal_title：Bone marrow transplantation

authors： Tarella C,Caracciolo D,Gavarotti P,Bondesan P,Cherasco C,Omedè P,Bregni M,Siena S,Gianni AM,Pileri A

更新日期：1995-08-01 00:00:00

abstract：:Threshold levels of CMV-specific T-cell populations presumably affording protection from active CMV infection in allo-SCT recipients have been proposed, but lack extensive validation. We quantified CMV pp65 and immediate-early 1-specific IFN-γ CD8(+) and CD4(+) T cell responses at days +30, +60 and +90 after transplan...

journal_title：Bone marrow transplantation

authors： Tormo N,Solano C,Benet I,Nieto J,de la Cámara R,López J,Garcia-Noblejas A,Muñoz-Cobo B,Costa E,Clari MA,Hernández-Boluda JC,Remigia MJ,Navarro D

更新日期：2011-11-01 00:00:00

abstract：:Localised Kaposi's sarcoma (KS) was diagnosed 240 days after allogeneic bone marrow transplantation (BMT) in a severely immunosuppressed HIV negative patient with genetic predisposition. The tumour was of host origin, based on PCR amplification of DNA minisatellites. Treatment with radiotherapy prompted almost complet...

journal_title：Bone marrow transplantation

authors： Helg C,Adatto M,Salomon D,Roux E,Miralbell R,Chapuis B,Saurat JH

更新日期：1994-12-01 00:00:00

abstract：:Two adult leukemia patients underwent allogeneic bone marrow transplantation and received cyclosporine (CsA) as part of their immunosuppressive therapy. Despite adequate kidney function, both patients developed hyperkalemia. Cyclosporine was the only pharmaceutical agent to which this electrolyte abnormality could be ...

journal_title：Bone marrow transplantation

authors： Fleming DR,Ouseph R,Herrington J

更新日期：1997-02-01 00:00:00

abstract：:Photodynamic therapy (PDT) with porphyrin precursors is an established therapy for certain tumors. This study aimed to explore the use of hexaminolevulinate (HAL), a porphyrin precursor, for photodynamic purging of BM grafts contaminated with cells of the 4T1 breast carcinoma cell line. The optimal PDT dose was not ef...

journal_title：Bone marrow transplantation

authors： Čunderlíková B,Vasovič V,Sieber F,Furre T,Borgen E,Nesland JM,Peng Q

更新日期：2011-08-01 00:00:00

abstract：:Budesonide (BUD) is a steroid with a low bioavailability, which has been used for the treatment of oral manifestations of chronic GVHD (cGVHD). We retrospectively evaluated the efficacy of BUD in the treatment of gastrointestinal cGVHD. Thirteen patients (median age 47 years) receiving BUD for the treatment of cGVHD a...

journal_title：Bone marrow transplantation

authors： Andree H,Hilgendorf I,Leithaeuser M,Junghanss C,Holzhueter S,Loddenkemper C,Steiner B,Freund M,Wolff D

更新日期：2008-10-01 00:00:00

abstract：:Rapid, specific and sensitive methods are essential for early detection of CMV infection in patients after marrow transplantation. Thus, in a prospective study, PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture were used and compared in 20 consecutive marrow transplant recipients for early diagnosis...

journal_title：Bone marrow transplantation

authors： Hebart H,Müller C,Löffler J,Jahn G,Einsele H

更新日期：1996-05-01 00:00:00

abstract：:There is substantial progress in preventing and treating cytomegalovirus (CMV) infections and CMV-related disease after allogeneic bone marrow transplantation. In CMV-seronegative recipients, use of CMV-seronegative blood products eliminates most CMV infections. Effective prophylaxis for CMV-seropositive recipients is...

journal_title：Bone marrow transplantation

authors： Winston DJ,Gale RP

更新日期：1991-07-01 00:00:00

abstract：:The purpose of this study was two-fold: to describe the quality of life and behavioral adjustment of survivors of pediatric bone marrow transplantation (BMT) prior to and 6 months post-BMT; and, to identify correlates of survivors' quality of life and behavioral adjustment. Participants were 26 children and adolescent...

journal_title：Bone marrow transplantation

authors： Barrera M,Boyd-Pringle LA,Sumbler K,Saunders F

更新日期：2000-08-01 00:00:00

abstract：:With the increasing use and success of BMT, larger numbers of children survive transplantation. Still, cancer treatment in children causes damage to the endocrine glands, often inducing growth deficiency, pubertal delay and thyroid dysfunction. This paper will deal with some of the most common endocrine disorders rela...

journal_title：Bone marrow transplantation

authors： Cohen A,Rovelli R,Zecca S,Van-Lint MT,Parodi L,Grasso L,Uderzo C

更新日期：1998-04-01 00:00:00

abstract：:Relapsed disease remains a major obstacle following autologous haematopoietic SCT (HSCT) for non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Studies regarding the importance of detectable tumour cells in PBSC collections have been inconclusive. Patients undergoing autologous HSCT for NHL and MM between 2001 an...

journal_title：Bone marrow transplantation

authors： Ho J,Yang L,Banihashemi B,Martin L,Halpenny M,Atkins H,Sabloff M,McDiarmid SA,Huebsch LB,Bence-Bruckler I,Giulivi A,Allan DS

更新日期：2009-02-01 00:00:00

abstract：:The purpose of this study was to measure the trajectory of psychosocial recovery over the first year after bone marrow transplantation (BMT). BMT patients were assessed at baseline (n = 86), hospital discharge (n = 74), 100 days (n = 64) and at 1 year (n = 45). Participants completed the Functional Assessment of Cance...

journal_title：Bone marrow transplantation

authors： McQuellon RP,Russell GB,Rambo TD,Craven BL,Radford J,Perry JJ,Cruz J,Hurd DD

更新日期：1998-03-01 00:00:00

abstract：:Adjuvant transfusion of donor lymphocytes (aDLT) may reduce the risk of relapse after allogeneic stem cell transplantation in high-risk AML. We performed a retrospective analysis on the safety and efficacy of aDLT in a cohort of 46 patients. To be eligible for aDLT, patients had to be in CR for at least 120 days from ...

journal_title：Bone marrow transplantation

authors： Jedlickova Z,Schmid C,Koenecke C,Hertenstein B,Baurmann H,Schwerdtfeger R,Tischer J,Kolb HJ,Schleuning M

更新日期：2016-05-01 00:00:00

abstract：:At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen. We thus performed a retrospective analysis to identify the risk factors for HVOD, which could explain such a ch...

journal_title：Bone marrow transplantation

authors： Cacchione A,LeMaitre A,Couanet DV,Benhamou E,Amoroso L,Simonnard N,Hartmann O

更新日期：2008-10-01 00:00:00

abstract：:There is a known increased risk of skin cancer in the adult population after hematopoietic stem cell transplantation (HSCT). However, late dermatologic effects that children may experience after HSCT have not been well described. The primary objective of this study was to characterize nevi and skin cancers affecting c...

journal_title：Bone marrow transplantation

authors： Song JS,London WB,Hawryluk EB,Guo D,Sridharan M,Fisher DE,Lehmann LE,Duncan CN,Huang JT

更新日期：2017-07-01 00:00:00

abstract：:YKL-40, also called chitinase-3-like-1 protein, is an inflammatory biomarker that has been associated with disease severity in inflammatory and malignant diseases, including AML, multiple myeloma and lymphomas. The objective of the current study was to assess the prognostic value of pretransplant recipient and donor p...

journal_title：Bone marrow transplantation

authors： Kornblit B,Wang T,Lee SJ,Spellman SR,Zhu X,Fleischhauer K,Müller C,Verneris MR,Müller K,Johansen JS,Vindelov L,Garred P

更新日期：2016-12-01 00:00:00

abstract：:Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, optimal dose and tapering schedule of ruxolitinib remain to be determined. Discontinuation of ruxolitinib in myelofibros...

journal_title：Bone marrow transplantation

authors： Mori Y,Ikeda K,Inomata T,Yoshimoto G,Fujii N,Ago H,Teshima T

更新日期：2016-12-01 00:00:00